Scienture Holdings, Inc.SCNX
▲ PositiveCapitalrelevance
Revenue surged 510% sequentially and net loss narrowed 58% YoY, indicating improved financial performance.
Impact on stocks 1
Biotech & Genomic Medicine
Scienture Holdings, Inc.Scienture Holdings reported second-quarter revenue of $0.34 million, a sequential increase of approximately 510 percent. Non-GAAP net loss per share was $0.07. Net loss narrowed 58 percent year-over-year to $2.82 million from $6.72 million. Gross profit was $0.34 million with a gross margin of approximately 97.7 percent. Cash, cash equivalents, and restricted cash totaled $11.20 million as of June 30, 2026. First-half 2026 revenue rose to $0.40 million from $0.01 million in the first half of 2025.
Scienture Holdings, Inc.Revenue surged 510% sequentially and net loss narrowed 58% YoY, indicating improved financial performance.